Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Dec 23, 2022 12:22pm
125 Views
Post# 35189709

RE:RE:RE:RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

RE:RE:RE:RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stockI have traded my way closer to break even thanks Noteable, from 95% down. I keep a core holding, usually at a loss (20-40% depending on market conditions), and I hold because in the next 6 months I believe there is still the potential to break even, and potentially double my investment. 

But as for thinking this is going up 10 times, or 25 times from current valuation is in my mind, pure hopium. Matt will either have to accept the offer he's given, or the company folds, as it simply cannot afford to run a phase III by itself, not without massive share dilution.

The question then becomes, is Bracelet-1 data compelling enough to drive such a deal. If it isn't, mBC is dead in the water... then it's all about Roche and Panc. So this is still very much a gamble, and given the track record of trials (let's ensure we include the disastrous Phase III for H&N) even good recent data is not a given. I will sell my core holding (at a loss if I have to) if a deal is not done in Q2 2023.

I'm no longer 100% in ONCY, so can no longer be wiped out if they fail.
<< Previous
Bullboard Posts
Next >>